[1] Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primers, 2016, 2: 16018.
[2] Wallce MC, Preen D, Gary PE, et al. The evolving epidemiology of hepatocellular carcinoma: a global perspective. Exp Rev Gasteoen Hepatol, 2015, 9(6): 765-779.
[3] Page AJ, Cosgrove DC, Philosophe B, et al. Hepatocellular carcinoma: diagnosis, management, and prognosis. Surg OncolClin N Am, 2014, 23(2): 289-311.
[4] Zhao CH, Zhou WF, Chen WH, et al. Clinical significanceof afetoprotein ininitial diagnosis of primary hepatic cancer. J Clin Hepatol, 2013, 29(9): 698-701.
[5] 孙启峰, 赵志强, 周童, 等. 腹腔镜肝部分切除术治疗肝癌患者血清肿瘤标志物的变化.实用肝脏病杂志, 2018, 21(1): 121-122.
[6] Li R, Yaa F, Liu L, et a1.Cytokine-induced killer cell therapy for the treatment of primary hepatocellular carcinoma subsequent to liver transplantation:a case report. Oneol Lett, 2016, 11(3): 1885-1889.
[7] 张志伟, 陈孝平. 《原发性肝癌诊疗规范》(2017)版解读. 临床外科杂志, 2018, 26(1): 5-8.
[8] Katyal S, Oliver JH, Peterson MS, et al. Exter hepatic metastases ofhepatic ellular carcinoma. Radiology, 2000, 226(3): 698-703.
[9] Du SP, Guo ZY, Chen BB, et al. Electrochemiluminescence immunosensor for tumor markers based on biologicalbar code mode with conductive nanospheres. Biosens Bioelectron, 2014, 53(3): 135-141.
[10] Yoshikawa M, Morine Y, Ikemoto T, et al. Elevated preoperative serum CEA level is associated with poor prognosis in patients with hepatocellular carcinoma through the epithelial-mesenchymal transition. Anticancer Res, 2017, 37(3): 1169-1175.
[11] Liu J, Xia Y, Shi L, et al. Elevated serum carcinoembryonic antigen is associated with a worse survival outcome of patients after liver resection for hepatocellular carcinoma: a propensity score matching analysis. J Gastrointest Surg, 2016, 20(12): 2063-2073.
[12] Lencioni R, deBaere T, Soulen MC, et al. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatology, 2016, 64: 106-116.
[13] Li DP, Li W, Feng J, et al. Adjuvant chemotherapy with sequential cytokine-in duced killer (CIK) cells in stage IB non-small cell lung cancer. Oncol Res, 2015, 22(2): 67-74.
[14] Marshall A, Lukk M, Kutter C, et al. Global gene expression profiling reveals SPINK1 as a potential hepatocellular carcinoma marker. PloS One, 2013, 8(3): e59459.
[15] Takayasu K, Arii S, Ikai I, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology, 2006, 131: 461-469.
[16] 刘泽龙, 王阳, 张国志, 等. 肝动脉栓塞化疗联合肝叶切除术治疗原发性肝癌患者临床疗效观察. 实用肝脏病杂志, 2017, 20(3): 368-369.
[17] 王琴, 张东成, 董超, 等. 三维适形放疗放射野布局对治疗原发性肝癌患者放射性肝损伤的影响. 实用肝脏病杂志, 2017, 20(3): 366-367.
[18] Yoon SM, Lim YS, Won HJ, et al. Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes. Int J Radiat Oncol Biol Phys, 2012, 82(5): 2004-2011.
[19] Han K, Kim JH, Yoon HM, et al. Transcatheter arterial chemoembolization for infiltrative hepatocellular carcinoma:clinical safety and efficacy and factors influencing patient survival. Korean J Radiol, 2014, 15(4): 464-471.
[20] Zhang HJ, Zhu XF. Clinical implementation of stereotactic body radiation therapy in pancreatic cancer and hepatocellular carcinoma. World Chin J Digestol, 2015, 23(25): 3989-3996. |